Canada markets closed

Addex Therapeutics Ltd (ADXN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8060+0.0077 (+0.96%)
At close: 04:00PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 7.42M
Enterprise Value -1.33M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)3.02
Price/Book (mrq)0.90
Enterprise Value/Revenue -0.89
Enterprise Value/EBITDA 0.07

Trading Information

Stock Price History

Beta (5Y Monthly) 1.76
52-Week Change 3-91.59%
S&P500 52-Week Change 3-16.88%
52 Week High 39.4500
52 Week Low 30.7430
50-Day Moving Average 31.1544
200-Day Moving Average 33.7631

Share Statistics

Avg Vol (3 month) 33.01M
Avg Vol (10 day) 3152.32k
Shares Outstanding 58.2M
Implied Shares Outstanding 6N/A
Float 84.57M
% Held by Insiders 10.00%
% Held by Institutions 115.64%
Shares Short (Aug 30, 2022) 4130.32k
Short Ratio (Aug 30, 2022) 40.33
Short % of Float (Aug 30, 2022) 4N/A
Short % of Shares Outstanding (Aug 30, 2022) 41.59%
Shares Short (prior month Jul 28, 2022) 4209.76k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in CHF.

Fiscal Year

Fiscal Year Ends Dec 30, 2021
Most Recent Quarter (mrq)Jun 29, 2022


Profit Margin 0.00%
Operating Margin (ttm)-1,302.76%

Management Effectiveness

Return on Assets (ttm)-78.64%
Return on Equity (ttm)-180.95%

Income Statement

Revenue (ttm)1.59M
Revenue Per Share (ttm)0.26
Quarterly Revenue Growth (yoy)-82.60%
Gross Profit (ttm)-9.69M
EBITDA -20.84M
Net Income Avi to Common (ttm)-21.07M
Diluted EPS (ttm)-3.2640
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)8.81M
Total Cash Per Share (mrq)1.4
Total Debt (mrq)336.95k
Total Debt/Equity (mrq)4.91
Current Ratio (mrq)2.55
Book Value Per Share (mrq)1.09

Cash Flow Statement

Operating Cash Flow (ttm)-16.16M
Levered Free Cash Flow (ttm)-8.47M